Collaboration between FAU Erlangen and Skoltech is supported by a joint DFG-RSF grant

Current collaboration between FAU Erlangen (Prof. A.Mokhir) and Skoltech (Prof. T.Zatsepin) is supported by a joint DFG-RSF grant. We will develop a technology for selective downregulation of cancer-related RNAs in cancer cells in vivo. This approach can become a breakthrough in siRNA therapeutics for cancer treatment.

Last year at September 28, 2018 we organized a joint Bavarian-Russian meeting “Chemistry meets Biomedicine” in FAU Erlangen https://www.chemie.nat.fau.de/files/2018/09/Bavarian_flaer02_230918.pdf. The goal of the meeting was to enhance Bavarian-Russian scientific relations at the chemistry biomedicine interface devoted to basic research and development of breakthrough technologies. Due to the high interest from both sides, we decided to make the meeting annually and now organize an extended conference in Skoltech, Moscow, Russia at September 19-21, 2019 https://cmb.skoltech.ru/ The conference is organized by the Skolkovo Institute of Science and Technology (www.skoltech.ru), the Emerging Field Initiative “Chemistry in live cells” (Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and STAEDTLER-Stiftung) (https://www.chemie.nat.fau.de/ak-mokhir/chemistry-in-live-cells/) and the Bavarian Academic Center for Central, Eastern and Southeastern Europe (BAYHOST https://www.uni-regensburg.de/bayhost/english/index.html).


poster_biomed-1-1

Conference became truly international – among speakers are researchers from Germany, Russia, Japan, Korea and New Zealand (https://cmb.skoltech.ru/speakers/). This conference will be diverse – session topics Include chemistry and delivery of DNA/RNA therapeutics, CRISPR/Cas9 technology, nanomaterials for biomedicine, DNA-protein interactions, and medicinal chemistry of natural products and small molecules (https://cmb.skoltech.ru/agenda/). 

Contact information:
Skoltech Communications
+7 (495) 280 14 81

Tweet about this on Twitter0Share on Facebook0Pin on Pinterest0Share on Tumblr0Share on VK